Current Issue

Researchers identify 5 subgroups of patients with type 2 diabetes

The Swedish study grouped patients based on six key variables, including presence of glutamate decarboxylase antibodies, age at diagnosis, body mass index, HbA1c level, and estimates of beta-cell function and insulin resistance.

Intensive BP control reduced long-term CV risk, new ACCORD follow-up finds

After four years of follow-up, patients who had received intensive treatment during the trial had similar systolic blood pressure (BP) to those who had been on standard treatment but lower rates of cardiovascular (CV) events.

Diabetes treatment in the elderly has improved, but complex regimens still common, study finds

Between 2007 and 2014, more Medicare beneficiaries were newly prescribed metformin, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter 2 inhibitors, while fewer received long-acting sulfonylureas or thiazolidinediones.

MKSAP quiz: Medication after transient ischemic attack

This month's quiz asks readers to choose a treatment for a 70-year-old man admitted to the hospital with a 1-hour episode of left arm and left leg weakness.

Spotlight on fenofibrate

Recent analyses of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial looked at the effects of fenofibrate on gout and cardiovascular events in patients with type 2 diabetes.

ACP recommends less intensive glucose control in most cases of type 2 diabetes

The evidence-based guidance statement from ACP calls for personalized goals and an HbA1c target between 7% and 8% for most patients with type 2 diabetes.

Topic-specific resources available through ACP Online Learning Center

The Online Learning Center offers more than 400 online learning activities and has a section specifically focused on endocrinology, diabetes, and metabolism.